422 related articles for article (PubMed ID: 36787939)
21. CD38 marks the exhausted CD8
Reolo MJY; Otsuka M; Seow JJW; Lee J; Lee YH; Nguyen PHD; Lim CJ; Wasser M; Chua C; Lim TKH; Leow WQ; Chung A; Goh BKP; Chow PKH; DasGupta R; Yeong JPS; Chew V
Front Immunol; 2023; 14():1182016. PubMed ID: 37377962
[TBL] [Abstract][Full Text] [Related]
22. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade.
Kang P; Liu D; Li L; Guo X; Ye Y; Li Y; Jiang Q; Lin S; Yuan Q
Cytokine; 2023 Mar; 163():156133. PubMed ID: 36724715
[TBL] [Abstract][Full Text] [Related]
23. Single-cell mass cytometric analysis of peripheral immunity and multiplex plasma marker profiling of non-small cell lung cancer patients receiving PD-1 targeting immune checkpoint inhibitors in comparison with platinum-based chemotherapy.
Neuperger P; Szalontai K; Gémes N; Balog JÁ; Tiszlavicz L; Furák J; Lázár G; Puskás LG; Szebeni GJ
Front Immunol; 2023; 14():1243233. PubMed ID: 37901220
[TBL] [Abstract][Full Text] [Related]
24. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
25. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
[TBL] [Abstract][Full Text] [Related]
26. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
27. Interferon-Gamma-Producing CD8
Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
[TBL] [Abstract][Full Text] [Related]
28. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z; Hsu MA; Gicobi JK; Xu T; Harrington SM; Zhang H; Pavelko KD; Hirdler JB; Lohse CM; Nabavizadeh R; Pessoa RR; Sharma V; Thompson RH; Leibovich BC; Dong H; Lucien F
J Immunol; 2023 Jun; 210(12):2029-2037. PubMed ID: 37163328
[TBL] [Abstract][Full Text] [Related]
29. Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
Ku BM; Kim Y; Lee KY; Kim SY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Eur J Immunol; 2021 Apr; 51(4):956-964. PubMed ID: 33506525
[TBL] [Abstract][Full Text] [Related]
30. Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors.
Ichiki Y; Fukuyama T; Ueno M; Kanasaki Y; Goto H; Takahashi M; Mikami S; Kobayashi N; Nakanishi K; Hayashi S; Ishida T
Transl Lung Cancer Res; 2022 Nov; 11(11):2192-2207. PubMed ID: 36519023
[TBL] [Abstract][Full Text] [Related]
31. Single-cell analysis of peripheral CD8
Khojandi N; Connelly L; Piening A; Hoft SG; Pherson M; Donlin MJ; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2023 Feb; 72(2):397-408. PubMed ID: 35907015
[TBL] [Abstract][Full Text] [Related]
32. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
Pai JA; Hellmann MD; Sauter JL; Mattar M; Rizvi H; Woo HJ; Shah N; Nguyen EM; Uddin FZ; Quintanal-Villalonga A; Chan JM; Manoj P; Allaj V; Baine MK; Bhanot UK; Jain M; Linkov I; Meng F; Brown D; Chaft JE; Plodkowski AJ; Gigoux M; Won HH; Sen T; Wells DK; Donoghue MTA; de Stanchina E; Wolchok JD; Loomis B; Merghoub T; Rudin CM; Chow A; Satpathy AT
Cancer Cell; 2023 Apr; 41(4):776-790.e7. PubMed ID: 37001526
[TBL] [Abstract][Full Text] [Related]
33. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
[TBL] [Abstract][Full Text] [Related]
34. NLRP4 negatively regulates type I interferon response and influences the outcome in anti-programmed cell death protein (PD)-1/PD-ligand 1 therapy.
Wang H; Xia L; Yao CC; Dong H; Yang Y; Li C; Ji WX; Sun RM; Duan HQ; Mengzhou W; Xia WM; Wang SJ; Ji P; Li Z; Jiao L; Wang Y; Lu S
Cancer Sci; 2022 Mar; 113(3):838-851. PubMed ID: 34927309
[TBL] [Abstract][Full Text] [Related]
35. The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Zhao Z; Liu S; Sun R; Zhu W; Zhang Y; Liu T; Li T; Jiang N; Guo H; Yang R
Front Immunol; 2023; 14():1085476. PubMed ID: 36960067
[TBL] [Abstract][Full Text] [Related]
36. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.
Salehi-Rad R; Lim RJ; Du Y; Tran LM; Li R; Ong SL; Ling Huang Z; Dumitras C; Zhang T; Park SJ; Crosson W; Kahangi B; Abascal J; Seet C; Oh M; Shabihkhani M; Paul M; Krysan K; Lisberg AE; Garon EB; Liu B; Dubinett SM
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730274
[TBL] [Abstract][Full Text] [Related]
37. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
38. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
Oyanagi J; Koh Y; Sato K; Teraoka S; Tokudome N; Hayata A; Akamatsu H; Ozawa Y; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2021 Nov; 22(6):e833-e841. PubMed ID: 34049821
[TBL] [Abstract][Full Text] [Related]
39. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A; Finetti P; Denicolai E; Greillier L; Boudou-Rouquette P; Goldwasser F; Lumet G; Ceccarelli M; Birnbaum D; Bedognetti D; Mamessier E; Barlesi F; Bertucci F; Tomasini P
J Transl Med; 2023 Sep; 21(1):637. PubMed ID: 37726776
[TBL] [Abstract][Full Text] [Related]
40. CD8
Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
